Reviewed against primary sources on 25 August 2026 · Darshan Singh, 23 years in pharmaceutical QC, QA and drug regulatory affairs (LinkedIn) The short answer There is no single document called the FDA guidelines for purified water system operation. The…
Horizant (gabapentin enacarbil) is an FDA-approved extended-release medication used to treat two serious neurological conditions: moderate-to-severe restless legs syndrome (RLS) and postherpetic neuralgia (PHN)—the debilitating nerve pain that follows shingles infection. Unlike standard gabapentin which requires three daily doses, Horizant…
Laricold Tablets contain paracetamol, phenylephrine hydrochloride and chlorpheniramine maleate. Laricold is a prescription medicine (Schedule G), used as directed by a doctor for relief of common cold symptoms such as fever, headache, body ache, a blocked or runny nose, sneezing…
Paediatric guide · India · Updated 2026 Cough Syrup for Children in India (2026): The Age Rules, and What to Do Instead There is no “best paediatric cough syrup” to name any more, and below five years the question is…
Formulation guide · India · Updated August 2026 Short answer: since 9 June 2026 there is no “best dry cough syrup you can buy” in India, because you can no longer buy one off the shelf. Notification G.S.R. 477(E) deleted…
Short answer · HPLC price in India There is no list price for a new pharma-grade HPLC in India — only quotes for a configuration Agilent, Waters, Shimadzu, Thermo Fisher and PerkinElmer do not publish Indian prices for their current…
MYQORZO (aficamten) represents a significant advancement in the management of obstructive hypertrophic cardiomyopathy (oHCM), a condition characterized by thickened heart muscle that obstructs blood flow out of the heart. Approved by the FDA in December 2025, it provides a targeted…
Short answer: what a pharma plant costs in India in 2026 The pharma manufacturing plant cost in India runs from roughly ₹5–15 crore for a small oral-solids unit, ₹50–80 crore for a mid-scale multi-formulation export-capable facility, and ₹170–355 crore for…
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved Lerochol (lerodalcibep-liga), a novel third-generation proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor developed by LIB Therapeutics, Inc. Lerochol is approved as an adjunct to diet and exercise to…
HYRNUO® (sevabertinib), a reversible tyrosine kinase inhibitor targeting HER2 (ERBB2), received FDA approval on November 19, 2025, under the accelerated approval pathway for a molecularly defined population of lung cancer patients [Approval Letter, November 19, 2025, Reference ID: 5698585]. This approval…